| 摘要 |
5,9-Cyclic ethers of 9-deoxyprostaglandin-F1 alpha -type compounds of the formula <IMAGE> in which the substituents are defined in Patent Claim 1, are prepared. These compounds are obtained by converting a compound of the formula <IMAGE> into a mercury compound of the formula <IMAGE> and subsequently subjecting this latter compound to a reductive removal of mercury, resulting in the formation of the ether. The compounds which are obtained may be used as antiinflammatory agents as well as for inhibiting blood platelet aggregation in vivo or in vitro. |
